NASDAQ: ACXPAcurx Pharmaceuticals Inc Stock Ownership - Who owns Acurx Pharmaceuticals?
Insider buying vs selling
Have Acurx Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jack H. Dean | Director | 2025-01-06 | 9,852 | $1.02 | $10.00kBuy |
| Robert J. Deluccia | Director | 2025-01-06 | 49,261 | $1.02 | $50.00kBuy |
| James J. Donohue | Director | 2025-01-06 | 9,852 | $1.02 | $10.00kBuy |
| David P. Luci | President and CEO | 2025-01-06 | 49,261 | $1.02 | $50.00kBuy |
| Carl Sailer | Director | 2025-01-06 | 24,631 | $1.02 | $25.00kBuy |
| Joseph C. Scodari | Director | 2025-01-06 | 24,631 | $1.02 | $25.00kBuy |
ACXP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ACXP insiders and whales buy or sell their stock.
ACXP Shareholders
What type of owners hold Acurx Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| David P. Luci | 55.03% | 1,147,541 | $2.86M | Insider |
| Robert J. Deluccia | 48.63% | 1,014,043 | $2.52M | Insider |
| Robert G. Shawah | 9.07% | 189,200 | $471.11k | Insider |
| Carl Sailer | 6.82% | 142,183 | $354.04k | Insider |
| Joseph C. Scodari | 1.33% | 27,708 | $68.99k | Insider |
| Jack H. Dean | 1.32% | 27,546 | $68.59k | Insider |
| James J. Donohue | 1.07% | 22,352 | $55.66k | Insider |
| Prospect Financial Services LLC | 0.95% | 19,883 | $49.51k | Institution |
| Susquehanna International Group LLP | 0.81% | 16,815 | $41.87k | Institution |
| Sabby Management LLC | 0.42% | 8,705 | $21.68k | Institution |
ACXP vs Biotech Stocks
Acurx Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.